I discuss issues pertaining to the practice of neuropathology -- including nervous system tumors, neuroanatomy, neurodegenerative disease, muscle and nerve disorders, ophthalmologic pathology, neuro trivia, neuropathology gossip, job listings and anything else that might be of interest to a blue-collar neuropathologist.
Tuesday, May 26, 2015
The Tumor Biomarker Series: EGFR
Epidermal growth factor receptor (EGFR) is the most frequently amplified oncogene in astrocytic tumors (>40% or GBMs and 5-10% of anaplastic astrocytomas). EGFR is far more often amplified in de novo GBMs as compared to secondary GBMs. About one-half of those GBMs with EGFR amplification also have specific EGFR mutations (the vIII mutant), which produce a truncated receptor with constitutive activity. Both EGFR amplification and EGFRvIII mutant are mutually exclusive with IDH mutations. So, what is the utility of EGFR testing? First, astrocytomas with EGFR amplification tend to be of higher grade. So if, for example, the diagnostician is vacillating between a WHO grade II and a WHO grade III tumor, positive EGFR amplification status would favor the latter. Secondly, EGFR amplification can also help distinguish between a small cell GBM (which would potentially harbor the amplification) from anaplastic oligodendrogliomas (which do not exhibit the amplification).
Subscribe to:
Post Comments (Atom)
Dr. Diamandis develops network to help pathologists interface with AI computational scientists
A neuropathology colleague in Toronto (Dr. Phedias Diamandis) is developing some amazing AI-based tools for pathology and academia. He hel...
-
Shannon Curran, MS with her dissection Shannon Curran, a graduate student in the Modern Human Anatomy Program at the University of Co...
-
Last summer I put up a post about a remarkable whole nervous system dissection that was carried out at the University of Colorado School of ...
No comments:
Post a Comment